Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
about
Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction networkNoncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex.Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies.Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.The proteasome and proteasome inhibitors in multiple myeloma.An overview of the role of carfilzomib in the treatment of multiple myeloma.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.The Influence of Metabolism on Drug Response in Cancer
P2860
Q33437045-C88E7680-CCFD-4E81-9279-6B48DF6CD243Q36303485-3A7F8FF7-DD95-4F68-A77A-247744E59C8DQ37684348-51544509-1CE0-4BAB-B021-FAE8CFA976CDQ38719829-C3F3CE6A-DD95-489C-8719-044F39286723Q38947310-AD474537-C399-4465-BD4A-8BD781999FB2Q41056091-4F65B40A-4C6F-4DDC-A2AA-D07AF0602EB3Q41316676-78F1113B-1371-484D-ADAF-DA4BE53AD890Q41554672-391811DE-0751-4BEA-9B42-15E0A376EEB7Q45324487-2552D653-1721-4E07-A63A-B02BECBD8E76Q46185130-6C84134E-5A78-4CEC-90E6-E9B4C3D38AA9Q47339695-D058CE70-7BD6-4B59-8E56-5047C912633AQ50035012-90C10FDE-B921-4410-A8AF-3B98EEEAAE8AQ50057730-62918171-3825-453D-92B3-3F3559BDFAE1Q53800155-12C91731-1357-46E6-B5A5-85C313DA49F0Q59136910-88758FFE-3DEB-47A4-BC9D-729933B2AFD5
P2860
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proteasome inhibitor-adapted m ...... in redox and energy metabolism
@en
Proteasome inhibitor-adapted m ...... n redox and energy metabolism.
@nl
type
label
Proteasome inhibitor-adapted m ...... in redox and energy metabolism
@en
Proteasome inhibitor-adapted m ...... n redox and energy metabolism.
@nl
prefLabel
Proteasome inhibitor-adapted m ...... in redox and energy metabolism
@en
Proteasome inhibitor-adapted m ...... n redox and energy metabolism.
@nl
P2093
P2860
P50
P356
P1433
P1476
Proteasome inhibitor-adapted m ...... in redox and energy metabolism
@en
P2093
G P Soriano
H S Overkleeft
H den Dulk
N Meeuwenoord
P2860
P2888
P304
P356
10.1038/LEU.2016.102
P577
2016-04-27T00:00:00Z